Back to Search
Start Over
Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)
- Source :
- Journal of Clinical Oncology. 26:16096-16096
- Publication Year :
- 2008
- Publisher :
- American Society of Clinical Oncology (ASCO), 2008.
-
Abstract
- 16096 Background: Bevacizumab (Bev), a monoclonal vascular endothelial growth factor (VEGF) antibody, has activity in mRCC. A surrogate biomarker that would accurately predict therapeutic VEGF inhi...
- Subjects :
- Cancer Research
Bevacizumab
biology
business.industry
VEGF receptors
urologic and male genital diseases
medicine.disease
Vascular endothelial growth factor
chemistry.chemical_compound
Oncology
chemistry
Renal cell carcinoma
Monoclonal
medicine
biology.protein
Cancer research
Biomarker (medicine)
Antibody
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........1998b94de03f9ca2a93151e5f4a7ff14
- Full Text :
- https://doi.org/10.1200/jco.2008.26.15_suppl.16096